Streetbeat News

Products Services

EVOK

Evoke Pharma (NASDAQ:EVOK) and EVERSANA have presented real-world data demonstrating that GIMOTI, a nasal spray for treating diabetic gastroparesis (DGP), reduces healthcare costs compared to oral metoclopramide. The data, presented at the American College of Gastroenterology 2023 Annual Meeting, shows that DGP patients treated with GIMOTI were less likely to visit the emergency department or be admitted to the hospital. Over a six-month period, GIMOTI patients spent approximately $15,000 less than those on oral metoclopramide.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:42 pm

APLM

Apollomics has announced two new cohorts in its global Phase 2 SPARTA study of Vebreltinib in non-small cell lung cancer and other solid tumors with MET dysregulation. The first cohort is evaluating the addition of vebreltinib to EGFR tyrosine kinase inhibitor for patients with EGFR-mutated NSCLC progressing on first line EGFR inhibitor therapy. The second cohort will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor. A separate, ongoing Phase 1/2 trial is exploring the safety and efficacy of combining vebreltinib with frontline osimertinib in patients with EGFR-mutated NSCLC.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:41 pm

ASND

Ascendis Pharma A/S (NASDAQ:ASND) plans to report its Q3 2023 financial results and provide a business update on November 7, 2023. The company also announced its intention to resubmit its NDA for TransCon PTH for adults with hypoparathyroidism to the FDA before mid-November 2023. A conference call and webcast will be hosted on the same day to discuss the financial results and operations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:39 pm

MTEK

Maris-Tech Ltd. (NASDAQ:MTEK) has received a $625,000 repeat order for its Opal platform from a leading Israeli defense company. The Opal platform is based on Maris-Tech's flagship Jupiter AI platform, which delivers real-time intelligence gathering and analytics. The company expects to deliver the units during 2023 and 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:38 pm

BKTI

BK Technologies Corporation (NYSE:BKTI) has developed a new tethering feature for its InteropONE service, enabling push-to-talk-over-broadband capabilities for users of the company's BKR 5000 and BKR 9000 radios. The feature allows users to connect BKR radios with Apple or Android smartphones, and make or receive calls using a smartphone's cellular or WiFi connection. The company believes this will improve service for public safety responders in mission critical situations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:37 pm

SIDU

Sidus Space (NASDAQ:SIDU) has successfully completed environmental testing of its AI-enhanced LizzieSat satellite, marking a critical milestone in preparation for the upcoming launch expected in the first quarter of 2024. The company has also obtained the necessary launch and operating license. The testing was completed by NTS Orlando.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:36 pm

HTCR

HeartCore has launched its product, Dashiwake, into the U.S. and Japanese markets.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:36 pm

MBOT

Microbot Medical has revealed short term follow up outcomes from its pivotal pre-clinical study. The study used 6 LIBERTY Systems, each reaching 8 targets, with 100% usability and technical success. No adverse events or complications were observed. The company expects to receive the final report this quarter and plans to submit the Investigational Device Exemption (IDE) application to the FDA, pending the report and completion of the verification and validation process.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:28 pm

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the validation of its European patent for a novel process for the production of SBP-101 in the UK, Italy, Germany, France, and Spain. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six. The patent is valid until 2039 and covers a shorter synthesis of SBP-101, which provides a scalable, efficient, and cost-effective manufacturing process.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:17 pm

AAPL

TSM

Apple has launched its latest Mac products featuring in-house developed M3 series processors, manufactured by TSMC. However, the supply chain has not seen a significant increase in related orders for the holiday season.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:16 pm